Attorney's Docket No.: 20381-003US1 / PCT04TL2

## AP3 Rec'd PCT/PTO 2 2 JUN 2008

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kenichiro Kosai et al.

Art Unit : Unknown

Serial No.: To Be Assigned

Examiner: Unknown

Filed

: Herewith

Title

: DRUG FOR PREVENTING OR TREATING HEART DISEASES COMPRISING CD9

**Mail Stop PCT** 

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the documents listed on the enclosed PTO-1449 form. Also enclosed is a search report issued in the corresponding International Application PCT/JP2004/019774.

Note that to meet the requirement for providing "a concise explanation of the relevance" of all references not in English, one may provide an English-language version of a search report in which the relevance of the cited references is indicated. See the Manual of Patent Examining Procedure, Section 609 A(3). An English translation of foreign language document ABB is not provided, as the above-mentioned search report is in English.

This statement is being filed with the application. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 6-22-06	y. Rochy Zaw	
	Y. Rocky Tsao Ph.D., J.D Artorney for Applicants Reg. No. 34,053	

Fish & Richardson P.C. Telephone: (617) 542-5070 Facsimile: (617) 542-8906

21362606.doc

CERTIFICATE	OF MAILING BY EXPRESS MAIL
Express Mail Label No	EL 980077076 US
	June 22, 2006
Date of Deposit	

10/584109

AP3 Rec'd PCT/PTO 2.2 JUN 2008 Sheet 1 of 2

Substitute Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 20381-003US1

Application No.
To Be Assigned

Information Disclosure Statement

Applicant Kenichiro Kosai et al.

**by Applicant** (Use several sheets if necessary)

Filing Date Herewith **Group Art Unit** 

(37 CFR §1.98(b))

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB.						·
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document	Publication	Country or			Trans	ation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	AJ							
	AK							
<u> </u>	AL							
	AM							
	AN	0						

	Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner	Desig.			
Initial	ID	Document		
	AO	Berditchevski, F., "Complexes of Tetraspanins with Integrins: More than Meets the Eye", Journal of		
	AO	Cell Science, Vol. 114, pp. 4143-4151, 2001.		
	AP	Dominguez-Jimenez, C. et al., "Involvement of a3 Integrin/Tetraspanin Complexes in the		
	AP	Angiogenic Response Induced by Angiotensin II", FASEB Journal, Vol 15, pp. 1457-1459, 2001.		
	AQ	Hashida, H. et al., "Clinical Significance of Transmembrane 4 Superfamily in Colon Cancer",		
	AQ	British journal of Cancer, Vol. 89, pp. 158-167, 2003		
		Higashiyama, S. et al., "The Membrane Protein CD9/DRAP 27 Potentiates the Juxtacrine Growth		
	AR	Factor Activity of the Membrane-anchored Heparin-binding EGF-like Growth Factor", The journal		
		of Cell Biology, Vol. 128, pp. 929-938, 1995.		
	AS	Iwamoto, R and Mekada E., "Heparin-binding EGF-like Growth Factor: A Juxtacrine Growth		
L	AS	Factor", Cytokine & Growth Factor Reviews, Vol. 11, pp. 335-344, 2000.		

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no	I t in conformance and not considered. Include copy of this form with
next communication to applicant	••

10/584109

AP3 Rec'd PCT/PTO 22.111N Sheet 2 of 2

Substitute Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No. 20381-003US1

To Be Assigned

**Information Disclosure Statement** by Applicant (Use several sheets if necessary)

Applicant Kenichiro Kosai et al.

Filing Date Herewith **Group Art Unit** 

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.			
Initial	ID D	Document		
	A T	Iwamoto, R. et al., "Heparin-binding EGF-like Growth Factor and ErbB Signaling is Essential for		
	AT	Heart Function", PNAS, Vol. 100, No. 6, pp. 3221-3226, 2003.		
		Jennings, L. K. et al., "The Activation of Human Platelets Mediated by Anti-human Platelet		
	AU	p24/CD9 Monoclonal Antibodies", The Journal of Biological Chemistry, Vol. 265, No. 7, pp. 3815-		
		3822, 1990.		
		Kirkland, G. et al., "Heparin-Binding EGF-Like Growth Factor mRNA Is Upregulated in the Peri-		
		Infarct Region of the Remnant Kidney Model: In Vitro Evidence Suggests a Regulatory Role in		
	AV	Myofibroblast Transformation", Journal of the American Society of Nephrology, Vol. 9, pp. 1464-		
		1473, 1998.		
		Klein-Soyer, C. et al. "CD9 Participates in Endothelial Cell Migration During In Vitro Wound		
	AW	Repair", Arterioscler. Thromb. Vasc Biol., Vol. 20, pp. 360-369, 2000.		
		Maecker, H. T. et al., "The Tetraspanin Superfamily: Molecular Facilitators", The FASEB Journal,		
	AX	Vol. 11, pp. 428-442, 1997.		
		Masellis-Smith, A. et Al., "Anti-CD9 Monoclonal Antibodies Induce Homotypic Adhesion of PRE-		
	AY	B Cell Lines by A Novel Mechanism", The Journal of Immunology, Vol. 144, No. 5, pp. 1607-1613,		
		1990.		
		Miyado, K. et al., "Requirements of CD9 on the Egg Plasma Membrane for fertilization", Science,		
	AZ	vol. 287, pp. 321-324, 2000.		
**		Miyagawa, Ji. et al., "Localization of Heparin-binding EGF-like Growth Factor in the Smooth		
	AAA	Muscle Cells and Macrophages of Human Atherosclerotic Plaques", J. Clin. Invest., Vol. 95, pp.		
	'""	404-411, 1995.		
		Morimoto, C. et al., "Epidermal Growth Factor: EGF (Heparin-binding EGF-like Growth Factor:		
	ABB	HB-EGF)", Clinical Endocrinology, Vol. 51, No. 12, 1137-1143, 2003.		
		Nakagawa, T. et al., "Amino-terminal Processing of Cell Surface Heparin-binding Epidermal		
Ì	ACC	Growth Factor-like Growth Factor Up-regulates Its Juxtacrine but Not its Paracrine Growth Factor		
1		Activity", The Journal of Biological Chemistry, Vol. 271, No. 48, pp. 30858-30863, 1996.		
		Nakamura, K. et al., "Importance of the Major Extracellular Domain of CD9 and the Epidermal		
		Growth Factor (EGF)-like Domain of Heparin-binding EGF-like Growth Factor for Up-regulation of		
	ADD	Binding and Activity", The Journal of Biological Chemistry, Vol. 275, No. 24, pp. 18284-18290,		
İ		2000.		
		Nakamura, Y. et al., "Immunohistochemical Distribution of CD9, Heparin Binding Epidermal		
	AEE	Growth Factor-like Growth Factor, and Integrin \alpha 3\beta 1 in Normal Human Tissues", The Journal of		
		Histochemistry & Cytochemistry, Vol. 49, No. 4, pp. 439-444, 2001.		
	4.00	Nakata, A. et al., "Localization of Heparin-Binding Epidermal Growth Factor-Like Growth Factor in		
	AFF	Human Coronary Arteries", Circulation, vol. 94, pp. 2778-2786, 1996.		
		Nishida, M. et al., "Localization of CD9, an Enhancer Protein for Proheparin-Binding Epidermal		
	AGG	Growth Factor-Like Growth Factor, in Human Atherosclerotic Plaques", Arterioscler Thromb Vasc		
		Biol., Vol 20, pp. 1236-1243, 2000.		
		Takemura, T. et al., "Coexpression of CD9 Augments the Ability of Membrane-bound Heparin-		
	AHH	binding Epidermal Growth Factor-like Growth Factor (pro HB-EGF) to Preserve Renal Epihelial		
		Cell Viability", Kidney International, Vol. 55, pp. 71-81, 1999.		
L	ı	1		

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with
next communication to applicant.	